Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two-Thirds Of Hepatitis C Patients Can See A Cure In Half The Time

15.09.2011
Response-guided treatment with drug telaprevir can be shortened to six months for many, says research published in New England Journal of Medicine

Treatment with a telaprevir-based combination regimen for hepatitis C – heretofore a chronic, destructive and difficult to manage disease – effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

Telaprevir, a drug approved for use against hepatitis C in May, inhibits replication of virus. This anti-viral drug and a similar medication called boceprevir have nearly doubled the number of patients with sustained response. Among patients treated with teleprevir, pegylated interferon and ribavirin in the new study, 72 percent were cured of their hepatitis C.

This study shows that two-thirds of patients can be cured in half the time: Patients who are clear of the virus within the first four to 12 weeks of therapy effectively can cut their treatment time from 48 weeks to six months. Besides the considerable benefits to patients of shorter treatment, these findings also show that response-guided therapy is a successful strategy.

“This means that rather than a one-size-fits-all approach, we can individualize treatment for patients based on their specific response to the drugs,” said Fred Poordad, MD, chief of Hepatology and Liver Transplantation at Cedars-Sinai and a senior author on the study. “Once you’re cured by these anti-viral drugs, you’re cured of hepatitis C completely. That’s a little known fact among the public – and even among physicians who don’t regularly treat liver disease.

Cedars-Sinai is one of the major research sites investigating new treatments for hepatitis C; the medical center is involved in developing most of these new compounds. Earlier this year, Dr. Poordad was the lead author of a study published in the New England Journal of Medicine on the anti-viral drug boceprevir, also an oral protease inhibitor. In that study, 1,097 patients with hepatitis C who had never been treated for the virus received standard treatment – pegylated interferon and ribavirin – for four weeks. Then, a third of the patients continued only on those drugs, while two other groups also received different durations of boceprevir. The boceprevir patients responded well, with 63 percent and 66 percent achieving sustained virus suppression – compared to 38 percent among patients taking only pegylated interferon and ribavirin.

According to the Centers for Disease Control, an estimated 3.2 million people in the United States have chronic hepatitis C virus infections. The disease is spread through virally infected blood, often by sharing of syringes or other equipment to inject drugs; prior to 1990, some infections can be attributed to blood transfusions. Some rare infections can be traced to medical procedures. Chronic hepatitis C is the leading cause of liver cancer and cirrhosis and is the chief reason for the need for liver transplants in the U.S. The disease is linked to as many as 10,000 deaths each year.

In the new telaprevir study, funded by Vertex Pharmaceuticals in Cambridge, Mass., a total of 540 patients were enrolled. They took a 12-week course of 750 milligrams of telaprevir three times a day in addition to therapy with pegylated interferon and ribavirin. Patients eligible for shortened treatment – meaning the virus was not detectable in the first month of treatment – were randomized to receive either 24 weeks or 48 weeks of treatment. The high cure rates among both groups showed that there was no benefit to additional treatment for early responders.

For patients, the shorter course of treatment means decreased costs, fewer side effects and less disruption to their daily lives, as this therapy requires intensive monitoring and laboratory visits.

Dr. Poordad has received research grants and served as an adviser and consultant for Vertex Pharmaceuticals, which makes telaprevir, and Merck, which makes boceprevir.

Sandy Van | Cedars-Sinai News
Further information:
http://www.cshs.org

Further reports about: Hepatitis Pharmaceuticals Two-Thirds anti-viral drug virus infection

More articles from Studies and Analyses:

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Oxygen loss in the coastal Baltic Sea is “unprecedentedly severe”
05.07.2018 | European Geosciences Union

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>